PMC:7283670 / 58492-58937 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T213","span":{"begin":431,"end":435},"obj":"Body_part"}],"attributes":[{"id":"A213","pred":"fma_id","subj":"T213","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"2020\nA Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging r"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T136","span":{"begin":431,"end":435},"obj":"Body_part"}],"attributes":[{"id":"A136","pred":"uberon_id","subj":"T136","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"2020\nA Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging r"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T351","span":{"begin":36,"end":44},"obj":"Disease"},{"id":"T352","span":{"begin":91,"end":99},"obj":"Disease"}],"attributes":[{"id":"A351","pred":"mondo_id","subj":"T351","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A352","pred":"mondo_id","subj":"T352","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"2020\nA Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging r"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T556","span":{"begin":5,"end":6},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T557","span":{"begin":110,"end":112},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T558","span":{"begin":431,"end":435},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T559","span":{"begin":431,"end":435},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"}],"text":"2020\nA Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging r"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T657","span":{"begin":63,"end":70},"obj":"Chemical"},{"id":"T36666","span":{"begin":154,"end":159},"obj":"Chemical"},{"id":"T59812","span":{"begin":161,"end":179},"obj":"Chemical"},{"id":"T48299","span":{"begin":161,"end":171},"obj":"Chemical"},{"id":"T80763","span":{"begin":172,"end":179},"obj":"Chemical"}],"attributes":[{"id":"A61051","pred":"chebi_id","subj":"T657","obj":"http://purl.obolibrary.org/obo/CHEBI_133748"},{"id":"A18394","pred":"chebi_id","subj":"T657","obj":"http://purl.obolibrary.org/obo/CHEBI_16947"},{"id":"A30512","pred":"chebi_id","subj":"T657","obj":"http://purl.obolibrary.org/obo/CHEBI_50744"},{"id":"A89545","pred":"chebi_id","subj":"T36666","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A63006","pred":"chebi_id","subj":"T59812","obj":"http://purl.obolibrary.org/obo/CHEBI_58987"},{"id":"A42763","pred":"chebi_id","subj":"T48299","obj":"http://purl.obolibrary.org/obo/CHEBI_9139"},{"id":"A46542","pred":"chebi_id","subj":"T80763","obj":"http://purl.obolibrary.org/obo/CHEBI_133748"},{"id":"A9226","pred":"chebi_id","subj":"T80763","obj":"http://purl.obolibrary.org/obo/CHEBI_16947"},{"id":"A98792","pred":"chebi_id","subj":"T80763","obj":"http://purl.obolibrary.org/obo/CHEBI_50744"}],"text":"2020\nA Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging r"}

{"project":"LitCovid-sentences","denotations":[{"id":"T620","span":{"begin":5,"end":51},"obj":"Sentence"},{"id":"T621","span":{"begin":52,"end":344},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"2020\nA Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging r"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T219","span":{"begin":377,"end":382},"obj":"Phenotype"}],"attributes":[{"id":"A219","pred":"hp_id","subj":"T219","obj":"http://purl.obolibrary.org/obo/HP_0001945"}],"text":"2020\nA Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging r"}

{"project":"LitCovid-PubTator","denotations":[{"id":"2109","span":{"begin":36,"end":44},"obj":"Disease"},{"id":"2110","span":{"begin":91,"end":99},"obj":"Disease"},{"id":"2111","span":{"begin":377,"end":382},"obj":"Disease"}],"attributes":[{"id":"A2109","pred":"tao:has_database_id","subj":"2109","obj":"MESH:C000657245"},{"id":"A2110","pred":"tao:has_database_id","subj":"2110","obj":"MESH:C000657245"},{"id":"A2111","pred":"tao:has_database_id","subj":"2111","obj":"MESH:D005334"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"2020\nA Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging r"}